

November 11, 2019

To,  
**SINGAPORE EXCHANGE SECURITIES  
TRADING LIMITED**  
11 North Buona Vista Drive,  
#06-07 The Metropolis Tower 2,  
Singapore – 138589

Dear Sir,

**Sub: Glenmark Pharmaceuticals receives ANDA approval for Adapalene and Benzoyl Peroxide  
Gel, 0.1%|2.5%**

With reference to the subject mentioned above, kindly find attached media release which is self explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,  
**For Glenmark Pharmaceuticals Limited**

HARISH Digitally signed  
by HARISH  
VINAYA VINAYAK KUBER  
K KUBER Date: 2019.11.11  
09:09:47 +05'30'

**Harish Kuber**  
**Company Secretary & Compliance Officer**

**Encl:** as above

**Glenmark Pharmaceuticals Ltd.**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)

**Press Release**

**For Immediate Release**

**Glenmark Pharmaceuticals receives ANDA approval for  
Adapalene and Benzoyl Peroxide Gel, 0.1%|2.5%**

**Mumbai, India; November 11, 2019:** Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Adapalene and Benzoyl Peroxide Gel, 0.1%|2.5%, the generic version of Epiduo®<sup>1</sup> Gel, 0.1%|2.5%, of Galderma Laboratories L.P.

According to IQVIA™ sales data for the 12 month period ending September 2019, the Epiduo® Gel, 0.1%|2.5% market<sup>2</sup> achieved annual sales of approximately \$33.7 million\*.

Glenmark's current portfolio consists of 163 products authorized for distribution in the U.S. marketplace and 45 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

<sup>1</sup>All brand names and trademarks are the property of their respective owners.

<sup>2</sup>Market includes brand and all available therapeutic equivalents

\*IQVIA™ National Sales Perspectives: Retail & Non-Retail, September 2019

-End-

**About Glenmark Pharmaceuticals**

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical organization. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2019). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is focused in the areas of oncology, dermatology and respiratory.

The company has a significant presence in the branded generics markets across emerging economies including India. Glenmark has 16 manufacturing facilities across five countries and has six R&D centers. The Generics business of Glenmark services the requirements of the US and Western European markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America and India.

**For further information, please contact:**

Madhurima Gupta Jain  
Glenmark, Mumbai, India  
Tel: +91 22 4018 9999  
Email: [corpcomm@glenmarkpharma.com](mailto:corpcomm@glenmarkpharma.com)